{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:37:30Z","timestamp":1778902650869,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5698,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1093\/annonc\/mdh221","type":"journal-article","created":{"date-parts":[[2004,5,19]],"date-time":"2004-05-19T17:18:09Z","timestamp":1084987089000},"page":"974-978","source":"Crossref","is-referenced-by-count":29,"title":["Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate"],"prefix":"10.1016","volume":"15","author":[{"given":"M.-H.","family":"Tay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.S.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.M.","family":"Regan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.B.","family":"Leibowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.G.","family":"Febbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Manola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.D.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.W.","family":"Kantoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.K.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh221_bb0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0090-4295(02)01579-0","article-title":"Osteoporosis during androgen deprivation therapy for prostate cancer","volume":"60","author":"Smith","year":"2002","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdh221_bb0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0090-4295(02)01576-5","article-title":"Antiandrogen monotherapy: indications and results","volume":"60","author":"Iversen","year":"2002","journal-title":"Urology"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdh221_bb0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000052339","article-title":"Quality of life issues relating to endocrine treatment options","volume":"36","author":"Iversen","year":"1999","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mdh221_bb0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(02)02006-X","article-title":"Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer","volume":"61","author":"Smith","year":"2003","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdh221_bb0030","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1210\/jcem-71-6-1552","article-title":"Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen","volume":"71","author":"Geller","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdh221_bb0035","doi-asserted-by":"crossref","first-page":"C113","DOI":"10.1016\/0303-7207(91)90116-A","volume":"78","author":"Intracrinology","year":"1991","journal-title":"Mol Cell Endocrinol"},{"key":"10.1093\/annonc\/mdh221_bb0040","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0090-4295(97)00091-5","article-title":"Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate","volume":"49","author":"Brufsky","year":"1997","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdh221_bb0045","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-5347(05)65970-8","article-title":"Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated","volume":"166","author":"Talcott","year":"2001","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdh221_bb0050","series-title":"Functioning and Well Being: The Medical Outcomes Study Approach","author":"Steward","year":"1992"},{"key":"10.1093\/annonc\/mdh221_bb0055","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/1097-0142(19930201)71:3+<1083::AID-CNCR2820711430>3.0.CO;2-1","article-title":"Antiandrogenic agents as monotherapy in advanced prostatic carcinoma","volume":"71","author":"Soloway","year":"1993","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh221_bb0060","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0022-5347(17)39757-4","article-title":"Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer","volume":"144","author":"Arai","year":"1990","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdh221_bb0065","first-page":"745","article-title":"A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer","volume":"45","author":"Schellhammer","year":"1995","journal-title":"Casodex Combination Study Group. Urology"},{"key":"10.1093\/annonc\/mdh221_bb0070","first-page":"814","article-title":"Evidence for atrophy and apoptosis in the prostates of men given finasteride","volume":"81","author":"Rittmaster","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdh221_bb0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0090-4295(99)80021-1","article-title":"Treatment with finasteride following radical prostatectomy for prostate cancer","volume":"45","author":"Andriole","year":"1995","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdh221_bb0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh221_bb0085","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0360-3016(02)02717-7","article-title":"Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer","volume":"53","author":"Hanlon","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdh221_bb0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0167-8140(96)01770-7","article-title":"Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate","volume":"40","author":"Zietman","year":"1996","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mdh221_bb0095","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2001.19.17.3750","article-title":"Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study","volume":"19","author":"Potosky","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419618430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419618430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/6\/974\/301486\/mdh221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T20:31:25Z","timestamp":1582230685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419618430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0923753419618430"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh221","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}